Insights

Orphan Oncology Focus Ascelia Pharma specializes in orphan oncology treatments, with drug candidates addressing unmet medical needs for liver lesions and difficult-to-treat cancers like gastric cancer.

Global Expansion With global headquarters in Sweden and a Nasdaq Stockholm listing, Ascelia Pharma has the potential to expand its market reach and attract international partners for drug commercialization.

Innovative Technology Adoption Utilizing a diverse tech stack including Google Analytics, Azure Active Directory, and Modernizr, Ascelia Pharma demonstrates a commitment to leveraging technology for efficient operations and data-driven decision-making.

Financial Health Despite a revenue range of $0 - 10M, Ascelia Pharma secured $10M in funding, indicating investor confidence in the company's growth potential and future profitability.

Competitive Positioning In a landscape with similar companies like Scandion Oncology and Pharvaris, Ascelia Pharma's focus on innovative oral chemotherapy drugs sets it apart and presents unique sales opportunities in the oncology market.

Similar companies to Ascelia Pharma AB

Ascelia Pharma AB Tech Stack

Ascelia Pharma AB uses 8 technology products and services including Google Analytics, MySQL, Azure Active Directory, and more. Explore Ascelia Pharma AB's tech stack below.

  • Google Analytics
    Analytics
  • MySQL
    Database
  • Azure Active Directory
    Identity And Access Management
  • Modernizr
    Javascript Libraries
  • Moment.js
    Javascript Libraries
  • Lodash
    Javascript Libraries
  • Bootstrap
    UI Frameworks
  • Apache
    Web Servers

Media & News

Ascelia Pharma AB's Email Address Formats

Ascelia Pharma AB uses at least 1 format(s):
Ascelia Pharma AB Email FormatsExamplePercentage
FL@ascelia.comJD@ascelia.com
33%
First.Last@ascelia.comJohn.Doe@ascelia.com
17%
FL@ascelia.comJD@ascelia.com
33%
First.Last@ascelia.comJohn.Doe@ascelia.com
17%

Frequently Asked Questions

Where is Ascelia Pharma AB's headquarters located?

Minus sign iconPlus sign icon
Ascelia Pharma AB's main headquarters is located at Hyllie Boulevard 34 Malmö, Skane County 215 32 SE. The company has employees across 2 continents, including EuropeNorth America.

What is Ascelia Pharma AB's official website and social media links?

Minus sign iconPlus sign icon
Ascelia Pharma AB's official website is ascelia.com and has social profiles on LinkedIn.

How much revenue does Ascelia Pharma AB generate?

Minus sign iconPlus sign icon
As of November 2024, Ascelia Pharma AB's annual revenue reached $3.8M.

What is Ascelia Pharma AB's NAICS code?

Minus sign iconPlus sign icon
Ascelia Pharma AB's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Ascelia Pharma AB have currently?

Minus sign iconPlus sign icon
As of November 2024, Ascelia Pharma AB has approximately 16 employees across 2 continents, including EuropeNorth America. Key team members include Chief Scientific Officer: A. L. N.Chief Financial Officer: D. G.Vice President Clinical Development: J. W.. Explore Ascelia Pharma AB's employee directory with LeadIQ.

What industry does Ascelia Pharma AB belong to?

Minus sign iconPlus sign icon
Ascelia Pharma AB operates in the Pharmaceutical Manufacturing industry.

What technology does Ascelia Pharma AB use?

Minus sign iconPlus sign icon
Ascelia Pharma AB's tech stack includes Google AnalyticsMySQLAzure Active DirectoryModernizrMoment.jsLodashBootstrapApache.

What is Ascelia Pharma AB's email format?

Minus sign iconPlus sign icon
Ascelia Pharma AB's email format typically follows the pattern of . Find more Ascelia Pharma AB email formats with LeadIQ.

How much funding has Ascelia Pharma AB raised to date?

Minus sign iconPlus sign icon
As of November 2024, Ascelia Pharma AB has raised $10M in funding. The last funding round occurred on Jul 10, 2024 for $10M.

When was Ascelia Pharma AB founded?

Minus sign iconPlus sign icon
Ascelia Pharma AB was founded in 2000.
Ascelia Pharma AB

Ascelia Pharma AB

Pharmaceutical ManufacturingSkane County, Sweden11-50 Employees

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

About Orviglance (Mangoral) 

Orviglance* (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.

About Oncoral

Oncoral is a novel oral irinotecan tablet in development. Irinotecan is a chemotherapy with established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Oncoral is initially developed for the treatment of gastric cancer, a cancer form with unmet needs and the opportunity for Orphan Drug status in the US and Europe. Following successful Phase 1 results, Phase 2 clinical development for Oncoral is in preparation.

*Trademark is registered in Europe and several other markets and submitted for registration in the US.

Section iconCompany Overview

Headquarters
Hyllie Boulevard 34 Malmö, Skane County 215 32 SE
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2000
Employees
11-50

Section iconFunding & Financials

  • $10M

    Ascelia Pharma AB has raised a total of $10M of funding over 2 rounds. Their latest funding round was raised on Jul 10, 2024 in the amount of $10M.

  • $10M

    Ascelia Pharma AB's revenue is in the range of $10M

Section iconFunding & Financials

  • $10M

    Ascelia Pharma AB has raised a total of $10M of funding over 2 rounds. Their latest funding round was raised on Jul 10, 2024 in the amount of $10M.

  • $10M

    Ascelia Pharma AB's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.